Evidence map›Paper›PMID 31886323›Full record

ArticleBone reports2020

Unique anabolic action of stem cell gene therapy overexpressing PDGFB-DSS6 fusion protein in OVX osteoporosis mouse model.

Wanqiu Chen, Samiksha Wasnik, Yawen Fu, Leslie Aranda, Charles H Rundle, Kin-Hing William Lau, David J Baylink, Xiaobing Zhang

Abstract read
In one paragraph

Article in Bone reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wanqiu ChenDepartment of Medicine, Division of Regenerative Medicine, Loma Linda University, Loma Linda, California, USA.
Samiksha WasnikDepartment of Medicine, Division of Regenerative Medicine, Loma Linda University, Loma Linda, California, USA.
Yawen FuDepartment of Medicine, Division of Regenerative Medicine, Loma Linda University, Loma Linda, California, USA.
Leslie ArandaDepartment of Medicine, Division of Regenerative Medicine, Loma Linda University, Loma Linda, California, USA.
Charles H RundleDepartment of Medicine, Division of Regenerative Medicine, Loma Linda University, Loma Linda, California, USA.
Kin-Hing William LauDepartment of Medicine, Division of Regenerative Medicine, Loma Linda University, Loma Linda, California, USA.
David J BaylinkDepartment of Medicine, Division of Regenerative Medicine, Loma Linda University, Loma Linda, California, USA.
Xiaobing ZhangDepartment of Medicine, Division of Regenerative Medicine, Loma Linda University, Loma Linda, California, USA.

Funding

BLR&D Research Career Scientist AwardIK6BX003782 · VA · VA LOMA LINDA HEALTHCARE SYSTEM · PI LAU, KIN-HING WILLIAM · 2017 to 2021
–
BLRD VA IK6 BX003782
6 · The paper itself

Abstract

In the present study we sought to improve the efficacy and safety of our Sca1

Indexed as

DSS6Fusion proteinOsteoporosisOVXPDGFBStem cell therapy

Identifiers

PMID31886323
PMCPMC6920713

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.